Provided by Tiger Fintech (Singapore) Pte. Ltd.

BeiGene

184.71
+0.0000
Volume:- -
Turnover:61.43M
Market Cap:19.67B
PE:-22.56
High:184.71
Open:184.71
Low:184.71
Close:184.71
Loading ...

BeiGene Enters Global Licensing Agreement with CSPC Zhongqi for Experimental Cancer Therapy

MT Newswires Live
·
13 Dec 2024

CSPC Pharmaceutical Group Grants Exclusive License of Cancer Inhibitor to BeiGene Switzerland

MT Newswires Live
·
13 Dec 2024

CSPC Pharmaceutical Partners with BeiGene on Innovative Cancer Drug

TIPRANKS
·
13 Dec 2024

BeiGene announces global licensing agreement for MAT2A inhibitor

TIPRANKS
·
13 Dec 2024

BeiGene’s Strong Pipeline and Financial Position Make It a Compelling Buy Opportunity

TIPRANKS
·
11 Dec 2024

BeiGene Secures $400 Million Facility from China Merchants Bank

MT Newswires Live
·
11 Dec 2024

Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading

MT Newswires Live
·
10 Dec 2024

Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025

Stock Track
·
10 Dec 2024

China Healthcare Sector's Recovery Momentum May Continue in 2025 -- Market Talk

Dow Jones
·
10 Dec 2024

BeiGene discloses new data in BRUKINSA, promising advancements pipeline at ASH

TIPRANKS
·
10 Dec 2024

BeiGene Ltd Announces New Share Options and RSUs

TIPRANKS
·
04 Dec 2024

BeiGene Gains Overweight Rating from Morgan Stanley with $300 Price Target

GuruFocus
·
04 Dec 2024

Why Is BeiGene, Ltd. (BGNE) Among the Best High Growth Healthcare Stocks to Invest In Now?

Insider Monkey
·
03 Dec 2024

Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

MT Newswires Live
·
29 Nov 2024

Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List

MT Newswires Live
·
29 Nov 2024

Stock Track | BeiGene Soars 5.37% as Four Drugs Gain National Insurance Coverage in China

Stock Track
·
29 Nov 2024